
Shandong Weigao Blood is a dialysis products manufacturer making hemodialyzers, dialysis machines, bloodlines, and peritoneal dialysis solutions.
wego-healthcare.comCrawled Nov 13, 2026
Weigao Group, founded in 1988, operates ten major industry clusters—including medical products, blood purification, orthopedics, biotechnology, pharmaceuticals, cardiovascular consumables, medical commerce, real estate, financing, and tourism and catering services—across over 60 subsidiaries and employs approximately 30,000 people globally.
Shandong Weigao Blood Purification is renaming to **Shandong Weigao Life Technology** after acquiring **Weigao Prefill**. The company files the change on the Shanghai Stock Exchange, expanding its focus beyond blood purification products.
Shandong Weigao Blood Purification Products Co. Ltd. (XSSC:603014) joins the S&P Global BMI Index. The company specializes in blood purification products and operates under the Shandong Weigao Group. This inclusion reflects its growing prominence in the medical device sector.
Shandong Wego Blood Purification acquires full ownership of Shandong WEGO Prefills Pharmaceutical Packaging, a manufacturer of prefillable syringes, via a share issuance. The move expands the company’s capabilities in pharmaceutical packaging solutions. The transaction was finalized following a regulatory filing.
Shandong Weigao Blood Purification Products Co Ltd announces the resumption of trading for its CO shares, effective November 3. The company specializes in blood purification products and operates under the Shandong Weigao Group. This follows a prior trading halt.
Weigao Blood Purification Products Co., Ltd. secures approval for its initial public offering (IPO) on the Shanghai Stock Exchange. The company specializes in hemodialysis and peritoneal dialysis products, with Huatai United Securities acting as its sponsor. The IPO aims to raise **1.351 billion yuan** in funding.
Shandong Weigao Group’s blood purification division is pursuing an initial public offering (IPO) on the Hong Kong Stock Exchange. The move targets expansion within the growing medtech sector, positioning it as the group’s fourth publicly listed entity. Weigao specializes in dialysis and related blood purification technologies.